Drug Type AAV based gene therapy |
Synonyms Desmoglein-2 AAV gene therapy (Renovacor), DSG2-associated ACM (Renovacor) |
Target |
Action modulators |
Mechanism DSG2 modulators(desmoglein 2 modulators), Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Arrhythmogenic Right Ventricular Dysplasia | Discovery | United States | 31 Oct 2022 | |
| Arrhythmogenic Right Ventricular Dysplasia | Discovery | United States | 31 Oct 2022 |





